Loading…
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $107M | $135M | $106M | $238M | 35.7% | 66.9% | - |
| 2024 | $64M | $-38M | $-56M | $-12M | -32.1% | 12.1% | - |
| 2023 | $57M | $-43M | $-55M | $-29M | -25.9% | 11.8% | -106.3% |
| 2022 | $51M | $-79M | $872M | $-188M | 197.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 51.35 | 57.42 | 64.38 | 107.46 |
| Operating Expense | 130.47 | 110.72 | 106.82 | 111.07 |
| Operating Income | -79.12 | -53.29 | -42.44 | -3.60 |
| EBITDA | -79.42 | -42.66 | -38.45 | 134.52 |
| EBIT | -86.45 | -46.92 | -42.07 | 131.71 |
| Pretax Income | -92.81 | -49.27 | -44.61 | 129.25 |
| Tax Provision | 0.01 | 5.92 | 11.80 | 23.35 |
| Net Income | 872.13 | -55.19 | -56.42 | 105.89 |
| Net Income Common Stockholders | 872.13 | -55.19 | -56.42 | 105.89 |
| Total Expenses | 130.47 | 110.72 | 106.82 | 111.07 |
| Interest Expense | 6.37 | 2.35 | 2.55 | 2.46 |
| Interest Income | 8.54 | 9.12 | 4.88 | 10.17 |
| Research And Development | 63.39 | 40.62 | 37.64 | 37.41 |
| Selling General And Administration | 67.07 | 70.09 | 69.17 | 73.65 |
| Normalized EBITDA | -63.55 | -39.92 | -33.94 | 59.38 |
| Normalized Income | -80.29 | -53.03 | -52.85 | 44.34 |
| Basic EPS | 11.85 | -1 | -1.15 | 2.10 |
| Diluted EPS | 11.85 | -1 | -1.15 | 2.06 |
| Tax Effect Of Unusual Items | -3.33 | -0.58 | -0.95 | 13.58 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.18 |
| Total Unusual Items | -15.87 | -2.74 | -4.51 | 75.14 |
| Total Unusual Items Excluding Goodwill | -15.87 | -2.74 | -4.51 | 75.14 |
| Net Income From Continuing Operation Net Minority Interest | -92.82 | -55.19 | -56.42 | 105.89 |
| Reconciled Depreciation | 7.02 | 4.26 | 3.62 | 2.81 |
| Net Interest Income | 2.18 | 6.77 | 2.33 | 7.71 |
| Net Income From Continuing And Discontinued Operation | 872.13 | -55.19 | -56.42 | 105.89 |
| Total Operating Income As Reported | -91.96 | -56.03 | -46.95 | -3.60 |
| Diluted Average Shares | 73.59 | 55.30 | 48.85 | 51.51 |
| Basic Average Shares | 73.59 | 55.30 | 48.85 | 50.32 |
| Diluted NI Availto Com Stockholders | 872.13 | -55.19 | -56.42 | 105.89 |
| Net Income Including Noncontrolling Interests | 872.13 | -55.19 | -56.42 | 105.89 |
| Net Income Discontinuous Operations | 964.96 | 0 | 0 | 0 |
| Net Income Continuous Operations | -92.82 | -55.19 | -56.42 | 105.89 |
| Other Income Expense | -15.87 | -2.74 | -4.51 | 125.14 |
| Other Non Operating Income Expenses | 0 | 0 | 0 | 50 |
| Special Income Charges | -15.87 | -2.74 | -4.51 | 75.14 |
| Gain On Sale Of Ppe | 0 | 0 | 0 | 75.14 |
| Other Special Charges | 3.03 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 4.51 | 0 |
| Restructuring And Mergern Acquisition | 12.84 | 2.74 | 0 | 0 |
| Earnings From Equity Interest | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 2.18 | 6.77 | 2.33 | 7.71 |
| Interest Expense Non Operating | 6.37 | 2.35 | 2.55 | 2.46 |
| Interest Income Non Operating | 8.54 | 9.12 | 4.88 | 10.17 |
| Operating Revenue | 51.35 | 57.42 | 64.38 | 107.46 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Theravance Biopharma, Inc.this co. | TBPH | $859M | 8.09↓ discount | 2.87 | 35.7% | -296.42 |
| LB Pharmaceuticals Inc | LBRX | $877M | - | 2.57 | -8.4% | -20.06 |
| Bright Minds Biosciences Inc. | DRUG | $872M | - | 10.63 | -14.9% | - |
| Talkspace, Inc. | TALK | $869M | 129.75 | 7.39 | 6.7% | 128.51 |
| SELLAS Life Sciences Group, Inc. | SLS |
| $862M |
| - |
| 10.09 |
| -37.9% |
| - |
| Janux Therapeutics, Inc. | JANX | $860M | - | 0.89 | -11.9% | 0.55 |
| EVMN | EVMN | $859M | - | 3.66 | -33.5% | -8.93 |
| MannKind Corporation | MNKD | $849M | 137.50 | -16.57 | -11.5% | 19.49 |
| Omada Health, Inc. | OMDA | $841M | - | 3.60 | -5.6% | -94.35 |
| Peer Median | - | 133.63 | 3.63 | -11.7% | -4.19 | |